REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

Current tag:

Thermo Fisher’s BRIMS-strategy

Translating fishing expeditions into targeted assays

(C) B2Bioworld 2010 July 2010. With its business development approach Thermo Fisher benefits from growing demand for mass spectrometry in clinical biomarker research. Still, nagging questions by competitors and end-users remain about validity of measurements, inter-changeability of experimental data, and harmonisation of standards across different instrumentation platforms.

Related Articles

Handling Suppliers of Mass Spectrometers Delicately

Michael P. Myers, Group Leader, Protein Networks at the International Centre for Genetic Engineering and Biotechnology, Trieste (IT)

A Global View on Interconnectivity, Quality, Harmonisation of Standards of Laboratory Automation and Biomanufacturing

Oskar-Werner Reif, CSO Sartorius on harmonisation of standards

Everyone re-invents the wheel

Michael Collasius, Vice President Automated Systems Qiagen NV on industry-wide standards for laboratory instruments

Electrophoresis in Proteomics: Some common Pitfalls and Ways to Avoid Them

Reiner Westmeier, Hans-Peter Schickle, Gelcompany - impartial technical advice and a look behind lab doors

If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

Handling Suppliers of Mass Spectrometers Delicately

(C) B2Bioworld 2010 July 2010. Michael P. Myers, Group Leader, Protein Networks at the International Centre for Genetic Engineering and Biotechnology, Trieste (IT) tells how he is avoiding to get trapped by manufacturers of mass spectrometers and their strategies to fend off competitors with proprietary data formats.

Customs Sequencing Markets

Worldwide evolution of the market and upcoming business opportunities

Thermo Fisher’s BRIMS-strategy.

Translating fishing expeditions into targeted assays.Thermo Fisher benefits from growing demand for mass spectrometry in clinical biomarker research. Still, nagging questions by competitors and end-users remain.

Everyone re-invents the wheel

Michael Collasius on a major issue for manufacturers of automated screening systems resp. laboratory instruments is establishing standards across single product lines and beyond in-house solutions.

We need the users, and users have to adopt it

Oscar-Werner Reif: A Global View on Interconnectivity, Quality, Harmonisation of Standards of Laboratory Automation and Biomanufacturing.